Men's Health Therapeutics Market to 2017 - Availability of Generic Sildenafil from 2012 to Restrain Market Growth - GBI Research Reports

Men's Health Therapeutics Market to 2017 - Availability of Generic Sildenafil from 2012 to Restrain Market Growth

Men's Health Therapeutics Market to 2017 - Availability of Generic Sildenafil from 2012 to Restrain Market Growth - GBI Research Reports
Men's Health Therapeutics Market to 2017 - Availability of Generic Sildenafil from 2012 to Restrain Market Growth
Published Jan 16, 2012
130 pages — Published Jan 16, 2012
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest research Men's Health Therapeutics Market to 2017 - Availability of Generic Sildenafil from 2012 to Restrain Market Growth. The report provides in-depth analysis of drivers and barriers that impact the global mens health therapeutics market. The report analyzes the markets for mens health in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, market revenue, and the annual cost of treatment (ACT) are forecast until 2017 for the key geographies, as well as the leading therapeutic segments. Furthermore, the report provides profiles of the leading companies, and analyzes the mergers and acquisitions (M&As) and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

GBI Research finds that the mens health therapeutics market will continue to grow only moderately. The principal reason for this stagnancy will be the first patent expiry of a top selling blockbuster, Viagra. The overall mens health market is driven by the launch of late-stage pipeline candidates and the steady increase in the diseased and treated population. The erectile dysfunction (ED) and benign prostatic hyperplasia (BPH) markets constitute a major portion of the mens health market. In 2010, these markets accounted for more than 80% of the total mens health therapeutics market. Male hypogonadism accounted for 8.6% of the total market size. The premature ejaculation market represents a small portion of the total mens health market. The premature ejaculation market does not have any FDA approved products in the major market geographies. However, it will grow at a higher rate during the forecast period compared to the erectile dysfunction and male hypogonadism market. This is because the premature ejaculation market will see the launch of promising new drugs in the future. In 2009, the global mens health therapeutics market was estimated to be worth $9,162m. GBI Research forecasts the market to grow at a compound annual growth rate (CAGR) of approximately 4.1% between 2010 and 2017 to record a sales value of approximately $12,163m by 2017.

The mens health market has a moderate level of unmet needs. The current treatment options in the erectile dysfunction and male hypogonadism market are efficacious and have a manageable safety profile with the exception of some rare but serious side effects. The unmet need in the premature ejaculation market is huge. This is because the market lacks any FDA approved products for treatment of the disease in major geographies. There exists an opportunity for pharmaceutical companies to produce drugs with improved efficacy, improved patient compliance and competitive pricing in the future. The mens health pipeline does contain few potential drugs which will help sustain market growth in the forecast period. However, the mens health Research and Development (R&D) pipeline is not very innovative, with most of the projects in the late stage pipeline being me-too products.

Scope

- Annualized market data for the mens health therapeutics market from 2002 to 2010 and forecast to 2017.
- Analysis of the leading therapeutic segments, including erectile dysfunction, male hypogonadism, premature ejaculation and benign prostatic hyperplasia.
- Analysis of the mens health therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the mens health therapeutics market, including market size, revenue analysis by top seven geographies, generic share, annua

  
Source:
Document ID
GBIHC173MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents38
  List of Tables53
  List of Figures83
Men s Health Therapeutics Market to 2017 - Introduction111
  Overview111
  GBI Research Report Guidance111
Men s Health Therapeutics Market to 2017 - Market Characterization1212
  Overview121
  Market Forecasts131
  Global Generic/Off-label Share141
  Annual Cost of Treatment151
  Treatment Usage Patterns162
    Diseased Population181
    Treatment Seeking Population191
    Diagnosed Population201
    Treated Population211
    Drivers and Restraints of the Men s Health Therapeutics Market221
      Market Drivers221
      Market Restraints231
Men s Health Therapeutics Market To 2017 - Geographical Landscape2416
  Market Forecasts by Country242
  The US261
    Market Forecasts261
    Annual Cost of Treatment271
    Treatment Usage Patterns281
      Diseased Population291
      Treatment Seeking Population291
      Diagnosed Population291
      Treated Population291
  Top Five Countries in Europe301
    Market Forecasts302
    Annual Cost of Treatment321
    Treatment Usage Patterns331
      Diseased Population341
      Treatment Seeking Population341
      Diagnosed Population341
      Treated Population341
  Japan351
    Market Forecasts351
    Annual Cost of Treatment361
    Treatment Usage Patterns371
      Diseased Population381
      Treatment Seeking Population381
      Diagnosed Population381
      Treated Population391
Men s Health Therapeutics Market to 2017 - Therapeutic Landscape4045
  Global Erectile Dysfunction (ED) Therapeutics Market401
    Market Overview401
    Market Forecasts402
    Revenue Analysis by Country422
    Global Generic/Off-Label Share441
    Annual Cost of Treatment451
    Treatment Flow Algorithm461
    Treatment Usage Patterns471
      Diseased Population481
      Treatment Seeking Population481
      Diagnosed Population481
      Treated Population491
    Product Analysis491
      Viagra (sildenafil citrate)491
      Cialis (tadalafil)491
      Levitra (vardenafil HCL)501
      Muse (alprostadil)501
    Drivers and Restraints of the ED Therapeutics Market501
      Market Drivers501
      Market Restraints511
  Global Male Hypogonadism Therapeutics Market511
    Market Overview511
    Market Forecasts521
    Revenue Analysis by Country532
    Global Generic/Off-label Share551
    Annual Cost of Treatment561
    Treatment Flow Algorithm571
    Treatment Usage Patterns581
      Diseased Population591
      Treatment Seeking Population591
      Diagnosed Population601
      Treated Population601
    Product Analysis611
      Gels (AndroGel, Testim and Fortesta)611
      Injections (Depo-Testosterone, Nebido, Delatestryl):621
      Transdermals (Androderm, Testoderm, Axiron)621
      Buccal Tablet (Striant)621
      Pellet Implants621
    Drivers and Restraints of the Male Hypogonadism Therapeutics Market631
      Market Drivers631
      Market Restraints631
  Global Premature Ejaculation (PE) Therapeutics Market631
    Market Overview631
    Market Forecasts641
    Revenue by Country652
    Global Generic/Off-Label Share671
    Annual Cost of Treatment681
    Treatment Flow Algorithm691
    Treatment Usage Patterns701
      Diseased Population711
      Treatment Seeking Population/Diagnosed Population711
      Treated Population711
    Product Analysis721
      Prozac/Sarafem (fluoxetine)721
      Paxil (paroxetine)721
      Zoloft (sertraline)721
      Priligy (dapoxetine)721
      Anafranil (clomipramine)721
      Lidocaine/prilocaine cream (EMLA cream)731
    Drivers and Restraints of the PE Therapeutics Market731
      Market Drivers731
      Market Restraints731
  Global Benign Prostatic Hyperplasia (BPH) Market741
    Overview741
    Market Forecasts742
    Revenue Analysis by Country761
    Generics/Off-Label Share771
    Annual Cost of Treatment781
    Treatment Flow Algorithm791
    Treatment Usage Patterns801
      Diseased Population811
      Treatment Seeking Population821
      Diagnosed Population821
      Treated Population821
    Product Analysis831
      Avodart (dutasteride)831
      Flomax (tamsulosin hydrochloride)831
      Cardura (doxazosin mesylate)831
      Uroxatral (Alfuzosin hydrochloride)831
    Drivers and Restraints of the BPH Therapeutics Market841
      Market Drivers841
      Market Restraints841
Men s Health Therapeutics Market to 2017 - Pipeline Analysis8519
  Overview851
  Research and Development Pipeline by Indication852
  Research and Development by Phase of Development871
  Research and Development Pipeline - Erectile Dysfunction881
    Pipeline by Clinical Phases of Development891
      Discovery891
      Preclinical/IND Filed891
      Phase I891
      Phase II891
      Phase III901
      NDA Filed901
    Profiles of Key Late-Stage Drugs in the Erectile Dysfunction Market901
      Avanafil901
      Zoraxel911
      Vitaros921
      Zydena (udenafil, DA-8159)921
  Research and Development Pipeline - Premature Ejaculation931
    Pipeline by Clinical Phases of Development941
      Discovery941
      Preclinical941
      Phase I941
      Phase II941
      Phase III951
    Profiles of Key Late-Stage Drugs in the Premature Ejaculation Market951
      PSD502/TEMPE951
  Research and Development Pipeline - Male Hypogonadism961
    Pipeline by Clinical Phases of Development971
      Preclinical971
      Phase I971
      Phase II971
      NDA Filed981
    Profiles of Key Late-Stage Drugs in the Male Hypogonadism Market981
      Bio-T-Gel981
      Aveed (testosterone Undecanoate)981
  Research and Development Pipeline - Benign Prostatic Hyperplasia991
    Pipeline by Clinical Phases of Development1001
      Preclinical1001
      Phase I1001
      Phase II1011
      Phase III1011
      NDA Filed1021
    Profiles of Key Late-Stage Drugs in the Benign Prostatic Hyperplasia Market1021
      NX-12071021
      PRX3021031
Men s Health Therapeutics Market to 2017 - Competitive Landscape1049
  Overview1041
  Company Profiles1041
    Pfizer Inc.1041
      Business Overview1041
      SWOT Analysis1041
    Eli Lilly and Company1051
      Business Overview1051
      SWOT Analysis1051
      Men s Health Product Pipeline1051
    GlaxoSmithKline, Inc1061
      Business Overview1061
      SWOT Analysis1061
      Men s Health Product Pipeline1061
    Abbott Laboratories1071
      Business Overview1071
      SWOT Analysis1071
      Men s Health Product Pipeline1071
    Endo Pharmaceuticals Holding Inc.1081
      Business Overview1081
      SWOT Analysis1081
      Men s Health Product Pipeline1081
    Bayer Healthcare AG1091
      Business Overview1091
      SWOT Analysis1091
      Men s Health Product Pipeline1091
    Johnson &Johnson1101
      Business Overview1101
      SWOT Analysis1101
    VIVUS, Inc.1111
      Business Overview1111
      SWOT Analysis1111
      Men s Health Product Pipeline1111
    Auxilium Pharmaceuticals, Inc.1121
      Business Overview1121
      SWOT Analysis1121
Men s Health Therapeutics Market to 2017 - Strategic Consolidations11310
  Overview1131
  Mergers and Acquisitions1141
    Overview1141
      Deals by Deals Value1141
      Deals by Geography1151
      Deals by Year1161
    Major M&A Deals1171
  Licensing Agreements1181
    Deals by Geography1181
    Deals by Value1191
    Deals by Year1201
  Major Licensing Agreements1211
  Co-Development Deals1221
    Major Co-Development Deals1221
Men s Health Therapeutics Market to 2017 - Appendix1238
  Market Definitions1231
  Abbreviations1231
  Research Methodology1246
    Coverage1241
    Secondary Research1251
    Primary Research1251
    Therapeutic Landscape1261
    Epidemiology-based Forecasting1262
    Market Size by Geography1281
    Geographical Landscape1291
    Pipeline Analysis1291
    Competitive Landscape1291
    Expert Panel Validation1291
  Contact Us1291
  Disclaimer1291
  Sources1301

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Men's Health Therapeutics Market to 2017 - Availability of Generic Sildenafil from 2012 to Restrain Market Growth" Jan 16, 2012. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Men-s-Health-Therapeutics-Market-to-2017-Availability-of-Generic-Sildenafil-from-2012-to-Restrain-Market-Growth-2115-343>
  
APA:
GBI Research Reports. (2012). Men's Health Therapeutics Market to 2017 - Availability of Generic Sildenafil from 2012 to Restrain Market Growth Jan 16, 2012. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Men-s-Health-Therapeutics-Market-to-2017-Availability-of-Generic-Sildenafil-from-2012-to-Restrain-Market-Growth-2115-343>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.